208 related articles for article (PubMed ID: 25499603)
1. Metformin and the risk of endometrial cancer: a population-based cohort study.
Ko EM; Stürmer T; Hong JL; Castillo WC; Bae-Jump V; Funk MJ
Gynecol Oncol; 2015 Feb; 136(2):341-7. PubMed ID: 25499603
[TBL] [Abstract][Full Text] [Related]
2. Metformin and endometrial cancer risk in Chinese women with type 2 diabetes mellitus in Taiwan.
Tseng CH
Gynecol Oncol; 2015 Jul; 138(1):147-53. PubMed ID: 25913129
[TBL] [Abstract][Full Text] [Related]
3. Metformin reduces ovarian cancer risk in Taiwanese women with type 2 diabetes mellitus.
Tseng CH
Diabetes Metab Res Rev; 2015 Sep; 31(6):619-26. PubMed ID: 25820555
[TBL] [Abstract][Full Text] [Related]
4. The effect of diabetes and metformin on clinical outcomes is negligible in risk-adjusted endometrial cancer cohorts.
Al Hilli MM; Bakkum-Gamez JN; Mariani A; Cliby WA; Mc Gree ME; Weaver AL; Dowdy SC; Podratz KC
Gynecol Oncol; 2016 Feb; 140(2):270-6. PubMed ID: 26607780
[TBL] [Abstract][Full Text] [Related]
5. Metformin vs sulfonylurea use and risk of dementia in US veterans aged ≥65 years with diabetes.
Orkaby AR; Cho K; Cormack J; Gagnon DR; Driver JA
Neurology; 2017 Oct; 89(18):1877-1885. PubMed ID: 28954880
[TBL] [Abstract][Full Text] [Related]
6. Metformin and the risk of endometrial cancer: a case-control analysis.
Becker C; Jick SS; Meier CR; Bodmer M
Gynecol Oncol; 2013 Jun; 129(3):565-9. PubMed ID: 23523618
[TBL] [Abstract][Full Text] [Related]
7. The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy.
Johannes CB; Koro CE; Quinn SG; Cutone JA; Seeger JD
Pharmacoepidemiol Drug Saf; 2007 May; 16(5):504-12. PubMed ID: 17245800
[TBL] [Abstract][Full Text] [Related]
8. Are sulfonylurea and insulin therapies associated with a larger risk of cancer than metformin therapy? A retrospective database analysis.
Kowall B; Rathmann W; Kostev K
Diabetes Care; 2015 Jan; 38(1):59-65. PubMed ID: 25336750
[TBL] [Abstract][Full Text] [Related]
9. Metformin does not affect cancer risk: a cohort study in the U.K. Clinical Practice Research Datalink analyzed like an intention-to-treat trial.
Tsilidis KK; Capothanassi D; Allen NE; Rizos EC; Lopez DS; van Veldhoven K; Sacerdote C; Ashby D; Vineis P; Tzoulaki I; Ioannidis JP
Diabetes Care; 2014 Sep; 37(9):2522-32. PubMed ID: 24898303
[TBL] [Abstract][Full Text] [Related]
10. Coronary heart disease outcomes in patients receiving antidiabetic agents.
McAfee AT; Koro C; Landon J; Ziyadeh N; Walker AM
Pharmacoepidemiol Drug Saf; 2007 Jul; 16(7):711-25. PubMed ID: 17551989
[TBL] [Abstract][Full Text] [Related]
11. Race, ethnicity, and use of thiazolidinediones among US adults with diabetes.
Aquilante CL; Zhang W; McCollum M
Curr Med Res Opin; 2007 Mar; 23(3):489-94. PubMed ID: 17355730
[TBL] [Abstract][Full Text] [Related]
12. Anti-diabetic therapies and the risk of acute pancreatitis: a nationwide retrospective cohort study from Taiwan.
Chang HY; Hsieh CF; Singh S; Tang W; Chiang YT; Huang WF
Pharmacoepidemiol Drug Saf; 2015 Jun; 24(6):567-75. PubMed ID: 25851403
[TBL] [Abstract][Full Text] [Related]
13. Comparative safety of diabetes medications and risk of incident invasive breast cancer: a population-based cohort study.
Calip GS; Yu O; Elmore JG; Boudreau DM
Cancer Causes Control; 2016 May; 27(5):709-20. PubMed ID: 27053250
[TBL] [Abstract][Full Text] [Related]
14. Protective effect of bisphosphonates on endometrial cancer incidence in data from the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial.
Alford SH; Rattan R; Buekers TE; Munkarah AR
Cancer; 2015 Feb; 121(3):441-7. PubMed ID: 25533883
[TBL] [Abstract][Full Text] [Related]
15. Cancer mortality reduction and metformin: a retrospective cohort study in type 2 diabetic patients.
Bo S; Ciccone G; Rosato R; Villois P; Appendino G; Ghigo E; Grassi G
Diabetes Obes Metab; 2012 Jan; 14(1):23-9. PubMed ID: 21812892
[TBL] [Abstract][Full Text] [Related]
16. Association Between Metformin Initiation and Incident Dementia Among African American and White Veterans Health Administration Patients.
Scherrer JF; Morley JE; Salas J; Floyd JS; Farr SA; Dublin S
Ann Fam Med; 2019 Jul; 17(4):352-362. PubMed ID: 31285213
[TBL] [Abstract][Full Text] [Related]
17. Sulfonylureas as Initial Treatment for Type 2 Diabetes and the Risk of Severe Hypoglycemia.
Yu O; Azoulay L; Yin H; Filion KB; Suissa S
Am J Med; 2018 Mar; 131(3):317.e11-317.e22. PubMed ID: 29032229
[TBL] [Abstract][Full Text] [Related]
18. Comparative Effect of Initiating Metformin Versus Sulfonylureas on Breast Cancer Risk in Older Women.
Hong JL; Jonsson Funk M; Buse JB; Henderson LM; Lund JL; Pate V; Stürmer T
Epidemiology; 2017 May; 28(3):446-454. PubMed ID: 28166101
[TBL] [Abstract][Full Text] [Related]
19. Metformin significantly reduces incident prostate cancer risk in Taiwanese men with type 2 diabetes mellitus.
Tseng CH
Eur J Cancer; 2014 Nov; 50(16):2831-7. PubMed ID: 25201464
[TBL] [Abstract][Full Text] [Related]
20. Differential Use of Screening Mammography in Older Women Initiating Metformin versus Sulfonylurea.
Hong JL; Henderson LM; Jonsson Funk M; Lund JL; Buse JB; Pate V; Stürmer T
Pharmacoepidemiol Drug Saf; 2017 Jun; 26(6):666-675. PubMed ID: 28370798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]